NASDAQ:AKRX - Akorn Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $3.59 0.00 (0.00 %) (As of 01/20/2019 04:00 PM ET)Previous Close$3.59Today's Range$3.56 - $3.7152-Week Range$3.14 - $33.27Volume2.82 million shsAverage Volume2.86 million shsMarket Capitalization$450.52 millionP/E RatioN/ADividend YieldN/ABeta2.85 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products, including Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. The company was founded in 1971 and is headquartered in Lake Forest, Illinois. Receive AKRX News and Ratings via Email Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:AKRX Previous Symbol CUSIP00972810 Webwww.akorn.com Phone847-279-6100Debt Debt-to-Equity Ratio1.26 Current Ratio3.47 Quick Ratio2.46Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$841.04 million Price / Sales0.54 Cash Flow$0.5264 per share Price / Cash Flow6.82 Book Value$6.65 per share Price / Book0.54Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-24,550,000.00 Net Margins-34.69% Return on Equity-14.97% Return on Assets-6.21%Miscellaneous Employees2,308 Outstanding Shares125,490,000Market Cap$450.52 million OptionableOptionable Akorn (NASDAQ:AKRX) Frequently Asked Questions What is Akorn's stock symbol? Akorn trades on the NASDAQ under the ticker symbol "AKRX." How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) posted its quarterly earnings data on Tuesday, November, 6th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.07 by $0.17. The firm had revenue of $165.63 million for the quarter, compared to the consensus estimate of $185.36 million. Akorn had a negative return on equity of 14.97% and a negative net margin of 34.69%. View Akorn's Earnings History. What price target have analysts set for AKRX? 6 equities research analysts have issued twelve-month price targets for Akorn's stock. Their predictions range from $6.00 to $34.00. On average, they anticipate Akorn's share price to reach $13.20 in the next year. This suggests a possible upside of 267.7% from the stock's current price. View Analyst Price Targets for Akorn. What is the consensus analysts' recommendation for Akorn? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akorn. Has Akorn been receiving favorable news coverage? News coverage about AKRX stock has trended neutral on Sunday, InfoTrie Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akorn earned a coverage optimism score of 0.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. Who are some of Akorn's key competitors? Some companies that are related to Akorn include Allakos (ALLK), Portola Pharmaceuticals (PTLA), PTC Therapeutics (PTCT), Corcept Therapeutics (CORT), Mallinckrodt (MNK), Pacira Pharmaceuticals (PCRX), Vanda Pharmaceuticals (VNDA), Zai Lab (ZLAB), Theravance Biopharma (TBPH), Enanta Pharmaceuticals (ENTA), Biohaven Pharmaceutical (BHVN), The Medicines (MDCO), Cambrex (CBM), Prestige Consumer Healthcare (PBH) and Aimmune Therapeutics (AIMT). Who are Akorn's key executives? Akorn's management team includes the folowing people: Mr. Rajat Rai, Chief Exec. Officer (Age 51)Mr. Duane A. Portwood, Exec. VP & CFO (Age 52)Dr. Bruce Kutinsky, Chief Operating Officer (Age 52)Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 53)Mr. Jonathan Kafer, Exec. VP of Sales & Marketing (Age 55) Who are Akorn's major shareholders? Akorn's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Retirement Systems of Alabama (0.47%), Louisiana State Employees Retirement System (0.03%), State of Alaska Department of Revenue (0.03%), Virtu Financial LLC (0.02%) and First Citizens Bank & Trust Co. (0.01%). Company insiders that own Akorn stock include Brian Tambi, Bruce Kutinsky, John N Kapoor and Joseph Bonaccorsi. View Institutional Ownership Trends for Akorn. Which major investors are buying Akorn stock? AKRX stock was purchased by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, State of Alaska Department of Revenue, Virtu Financial LLC, First Citizens Bank & Trust Co. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Akorn. How do I buy shares of Akorn? Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Akorn's stock price today? One share of AKRX stock can currently be purchased for approximately $3.59. How big of a company is Akorn? Akorn has a market capitalization of $450.52 million and generates $841.04 million in revenue each year. Akorn employs 2,308 workers across the globe. What is Akorn's official website? The official website for Akorn is http://www.akorn.com. How can I contact Akorn? Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected] MarketBeat Community Rating for Akorn (NASDAQ AKRX)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 474 (Vote Outperform)Underperform Votes: 390 (Vote Underperform)Total Votes: 864MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote "Outperform" if you believe AKRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2019 by MarketBeat.com StaffFeatured Article: What is the Federal Reserve?